Patents Assigned to Southern Research Institute
  • Patent number: 12215108
    Abstract: The present disclosure is concerned with purine diamine compounds for the treatment of conditions associated with BRD4, RIP3K, and/or IL6 signaling dysfunction such as, for example, cancer (e.g., lung cancer, skin cancer, bladder cancer, kidney cancer, liver cancer), arsenicosis, arsenic poisoning, inflammation, skin lesions, dysfunction of systemic organs, and skin blisters. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: January 10, 2023
    Date of Patent: February 4, 2025
    Assignees: Southern Research Institute, UAB Research Foundation, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Mark J. Suto, Bini Mathew, Corinne E. Augelli-Szafran, Marina Fosso Yatchang, Mohammad Athar, Anupam Agarwal, Ritesh Kumar Srivastava, Suhail Muzaffar, Jasim Khan
  • Patent number: 12208112
    Abstract: The present invention relates to pharmaceutical compositions for treating blood cancer, which includes 4?-thio-5-aza-2?-deoxycytidine (Aza-T-dCyd), and methods of treating blood cancer using a composition for oral administration that includes Aza-T-dCyd. The present invention provides a significant blood cancer therapeutic effect without having toxicity in a blood cancer mouse model or a human even with the Aza-T-dCyd dose conventionally known to have toxicity. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: April 22, 2021
    Date of Patent: January 28, 2025
    Assignees: Southern Research Institute, Pinotbio, Inc.
    Inventors: Mark J. Suto, Rebecca Boohaker, Doo Young Jung, Jin Soo Lee, Hyunyong Cho
  • Patent number: 12103943
    Abstract: The present disclosure is concerned with Clofarabine analogs for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: October 26, 2022
    Date of Patent: October 1, 2024
    Assignee: Southern Research Institute
    Inventors: Omar Moukha-Chafiq, Corinne Elizabeth Augelli-Szafran, Rebecca Boohaker, Larry D. Bratton, Marina Fosso Yatchang, Anish K. Vadukoot
  • Patent number: 12098216
    Abstract: The present disclosure is concerned with dipeptide compounds for the treatment of various cancers such as, for example, sarcomas, carcinomas, hematological cancers, solid tumors, breast cancer, cervical cancer, gastrointestinal cancer, colorectal cancer, brain cancer, skin cancer, prostate cancer, ovarian cancer, bladder cancer, thyroid cancer, testicular cancer, pancreatic cancer, endometrial cancer, melanomas, gliomas, leukemias, lymphomas, chronic myeloproliferative disorders, myelodysplastic syndromes, myeloproliferative neoplasms, and plasma cell neoplasms (myelomas). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 3, 2020
    Date of Patent: September 24, 2024
    Assignee: Southern Research Institute
    Inventors: Mark J. Suto, Bini Mathew, Rebecca Boohaker
  • Patent number: 11945781
    Abstract: The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: March 14, 2023
    Date of Patent: April 2, 2024
    Assignees: Southern Research Institute, UAB Research Foundation, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Mark J. Suto, Bini Mathew, Anupam Agarwal, Amie M. Traylor
  • Patent number: 11932626
    Abstract: The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 13, 2022
    Date of Patent: March 19, 2024
    Assignees: Southern Research Institute, Oregon Health and Science University
    Inventors: Ashish Kumar Pathak, Corinne E. Augelli-Szafran, Atefeh Garzan, Daniel Steblow, Nicole Haese
  • Patent number: 11905306
    Abstract: The present disclosure is concerned with substituted phenyl ethynyl pyridine carboxamide compounds, pharmaceutical compositions comprising the compounds, and methods of treating viral infections due to a Coronavirus such as, for example, Middle East respiratory syndrome coronavirus (MERS-CoV), severe acute respiratory syndrome coronavirus (SARS-CoV), and severe acute respiratory syndrome coronavirus disease 2019 (SARS-CoV-2), using the compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: December 21, 2022
    Date of Patent: February 20, 2024
    Assignees: Southern Research Institute, Vanderbilt University, University of North Carolina at Chapel Hill
    Inventors: Syed Kaleem Ahmed, Shilpa Dutta, John Phillip Tillotson, Corinne E. Augelli-Szafran, Ashish Kumar Pathak, Omar Moukha-Chafiq, Timothy Patrick Sheahan, Ralph S. Baric, Amy Catherine Sims, Mark R. Denison
  • Patent number: 11905258
    Abstract: The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-?B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 22, 2022
    Date of Patent: February 20, 2024
    Assignee: Southern Research Institute
    Inventors: Mark J. Suto, Bini Mathew, Rita Cowell, Corinne E. Augelli-Szafran
  • Patent number: 11858956
    Abstract: The present disclosure is concerned with 6-aza-nucleoside prodrugs that are capable of inhibiting a viral infection and methods of treating viral infections such as, for example, human immunodeficiency virus (HIV), human papillomavirus (HPV), chicken pox, infectious mononucleosis, mumps, measles, rubella, shingles, ebola, viral gastroenteritis, viral hepatitis, viral meningitis, human metapneumovirus, human parainfluenza virus type 1, parainfluenza virus type 2, parainfluenza virus type 3, respiratory syncytial virus, viral pneumonia, yellow fever virus, tick-borne encephalitis virus, Chikungunya virus (CHIKV), Venezuelan equine encephalitis (VEEV), Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), dengue (DENV), influenza, West Nile virus (WNV), zika (ZIKV), Middle East Respiratory Syndromes (MERS), Severe Acute Respiratory Syndrome (SARS), and coronavirus disease 2019 (COVID-19), using these compounds.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: January 2, 2024
    Assignees: Southern Research Institute, Oregon Health & Science University, Washington University in St. Louis, Board of Regents, The University of Texas System
    Inventors: Omar Moukha-Chafiq, Ashish Kumar Pathak, Shuklendu D. Karyakarte, Larry D. Bratton, Corinne E. Augelli-Szafran, Michael Diamond, Pei Yong Shi, Alec Jay Hirsch, Jessica Lee Smith, Daniel Streblow, Nicole Haese, Baoling Ying
  • Patent number: 11752153
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 3, 2022
    Date of Patent: September 12, 2023
    Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • Patent number: 11718593
    Abstract: The present disclosure is concerned with 2,5-amino-thiazole compounds that are capable of activating NF-?B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: May 16, 2019
    Date of Patent: August 8, 2023
    Assignee: Southern Research Institute
    Inventors: Mark J. Suto, Bini Mathew, Rita Cowell, Corinne E. Augelli-Szafran
  • Publication number: 20230172932
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Application
    Filed: November 3, 2022
    Publication date: June 8, 2023
    Applicants: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • Publication number: 20230159542
    Abstract: This disclosure provides compounds that inhibit RNA-binding proteins, such as Human antigen R protein (HuR). The compounds described herein have a high affinity for HuR multimers and inhibit the pathological processes that promote cancer and inflammation. The compounds are highly water-soluble and have good biodistribution for both systemic and central nervous system disease processes. The compounds provide a unique therapeutic option for disease processes related to neoplastic progression or acute or chronic inflammation.
    Type: Application
    Filed: April 21, 2021
    Publication date: May 25, 2023
    Applicants: THE UAB RESEARCH FOUNDATION, SOUTHERN RESEARCH INSTITUTE, THE UNITED STATES GOVERNMENT AS REPRESENTED BY THE DEPARTMENT OF VETERANS AFFAIRS
    Inventors: Louis B. Nabors, Natalia Filippova, Xiuhua Yang, Subramaniam Ananthan, Vibha Pathak, Peter King
  • Patent number: 11623918
    Abstract: The present disclosure is concerned with thioquinolinone compounds for the treatment of disorders associated with heme oxygenase-1 (HO-1) signaling dysfunction such as, for example, kidney diseases (e.g., chronic kidney disease, acute kidney injury). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: April 11, 2023
    Assignees: Southern Research Institute, UAB Research Foundation, The United States Government as Represented by the Department of Veterans Affairs
    Inventors: Mark J. Suto, Bini Mathew, Anupam Agarwal, Amie M. Traylor
  • Patent number: 11578073
    Abstract: The present disclosure is concerned with xanthine analogs, methods of making xanthine analogs, and methods of treating West Nile virus using these analogs. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: February 14, 2023
    Assignees: Southern Research Institute, Oregon Health and Science University
    Inventors: Ashish Kumar Pathak, Theresa Ha Nguyen, Corinne E. Augelli-Szafran, Alec Jay Hirsch, Jessica Lee Smith
  • Patent number: 11566019
    Abstract: The present disclosure is concerned with 2-pyrimidone compounds that are capable of inhibiting a viral infection and methods of treating alphavirus viral infections such as, for example, chikungunya, Eastern equine encephalitis (EEEV), Western equine encephalitis (WEEV), and Venezuelan equine encephalitis using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: April 2, 2021
    Date of Patent: January 31, 2023
    Assignees: Southern Research Institute, Oregon Health and Science University
    Inventors: Ashish Kumar Pathak, Corinne E. Augelli-Szafran, Atefeh Garzan, Daniel Streblow, Nicole Haese
  • Patent number: 11524010
    Abstract: In one aspect, compounds and compositions that inhibit TXNIP expression and/or that lower hepatic glucose production and methods of identifying, making, and using same are disclosed. The disclosed compounds and compositions can be useful for disorders associated with elevated TXNIP and/or elevated glucagon levels such as, for example, diabetes and associated disorders. Further provided are methods for treating hyperlipidemia or fatty liver disease, optionally associated with elevated TXNIP and/or elevated glucagon levels. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: July 13, 2021
    Date of Patent: December 13, 2022
    Assignees: SOUTHERN RESEARCH INSTITUTE, THE UAB RESEARCH FOUNDATION
    Inventors: Corinne E. Augelli-Szafran, Omar Moukha-Chafiq, Mark J. Suto, Anath Shalev, Lance Thielen, Junqin Chen, Gu Jing
  • Patent number: 11505531
    Abstract: The present disclosure is concerned with piperazine-2,5-diones that are capable of inhibiting TGF-? and methods of treating cancers such as, for example, multiple myeloma and a hematologic malignancy, and methods of treating fibrotic conditions using these compounds. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: August 5, 2019
    Date of Patent: November 22, 2022
    Assignees: UAB RESEARCH FOUNDATION, SOUTHERN RESEARCH INSTITUTE
    Inventors: Mark J. Suto, Vandana V. Gupta, Wei Zhang, Joanne Murphy-Ullrich
  • Patent number: 11478743
    Abstract: A thermochemical energy storage system and method of storing thermal energy are described. The energy storing system described herein comprises a reactor comprising: a) a reactor with a CO2 sorbent including MgO; and b) a supercritical CO2 source with supercritical CO2 and H2O, wherein the supercritical CO2 source is in fluid communication with the reactor and the CO2 sorbent including MgO to allow flow of the supercritical CO2 and H2O between the supercritical CO2 source and the reactor, thereby allowing contact of CO2 with the CO2 sorbent comprising MgO.
    Type: Grant
    Filed: September 18, 2019
    Date of Patent: October 25, 2022
    Assignee: Southern Research Institute
    Inventor: Andrew Jerome Muto
  • Patent number: 11472781
    Abstract: The present disclosure is concerned with 2-aminoaryl-5-aryloxazole compounds that are capable of activating NF-?B signaling. The present disclosure is also concerned with methods of using these compounds for the treatment of neurological disorders such as, for example, amyotrophic lateral sclerosis (ALS), Alzheimer's disease, Parkinson's disease, spinal muscular atrophy, traumatic brain injury, vascular dementia, Huntington's disease, mental retardation, and attention deficit and hyperactivity disorder (ADHD), and neuromuscular disorders such as, for example, Duchenne muscular dystrophy (DMD). This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.
    Type: Grant
    Filed: February 20, 2019
    Date of Patent: October 18, 2022
    Assignee: SOUTHERN RESEARCH INSTITUTE
    Inventors: Mark J. Suto, Bini Mathew, Rita Cowell, Corinne E. Augelli-Szafran